Researchers find novel mechanism of resistance to anti-cancer drugs
Oct. 17, 2017—Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.
New tools to combat kidney fibrosis
Oct. 13, 2017—Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.
Glowing receptors help find and track cancerous growth
May. 18, 2017—Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.
New target for colorectal cancer
Mar. 17, 2017—Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.
EGF receptor found to regulate macrophage inflammation in gut
Oct. 13, 2016—Researchers at Vanderbilt University School of Medicine have uncovered a link between epidermal growth factor receptor (EGFR) signaling and the inflammatory response to bacterial infection in the gastrointestinal tract.
Drug combos for glioblastoma
May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
Bad “traffic” linked to cancer
Sep. 3, 2015—Understanding how signaling molecules are transported within and out of the cell may help to uncover the causes of certain cancers.
Probing mutant EGF receptor regulation
Oct. 10, 2013—Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.
Plant compound stops colon cancer cells
Mar. 29, 2013—Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy.
HER2 may impact lung cancer therapy
Sep. 21, 2012—A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies.